Diagnosis & Differentiation
Verification of a Blood-Based Targeted Proteomics Signature for Malignant Pleural Mesothelioma
Cancer Epidemiology, Biomarkers, and Prevention 2020 July 30 [Link] Ferdinando Cerciello, Meena Choi, Sara L Sinicropi-Yao, Katie Lomeo, Joseph M Amann, Emanuela Felley-Bosco, Rolf A Stahel, Bruce W S Robinson, Jenette Creaney, Harvey I Pass, Olga Vitek, David P Carbone Abstract Background: We have verified a mass spectrometry (MS)-based targeted proteomics signature for the detection…
Read MoreDeterminants of plasma calretinin in patients with malignant pleural mesothelioma
BMC Research Notes 2020 July 29 [Link] Martin Lehnert, Daniel G Weber, Dirk Taeger, Irina Raiko, Jens Kollmeier, Susann Stephan-Falkenau, Thomas Brüning, Georg Johnen, MoMar-Study Group Abstract Objective: Calretinin is a well-known immunohistochemical tissue marker in the diagnosis of malignant mesothelioma. Promising results also indicate the use in early detection. In the present cross-sectional survey,…
Read MoreNew vistas in malignant mesothelioma: MicroRNA architecture and NRF2/MAPK signal transduction
Life Sciences 2020 July 22 [Link] Manav Gandhi, Sujit Nair Abstract Malignant mesothelioma (MM) is a cancer of the mesothelial lining of the pleura, peritoneum, pericardium and testes. The most common form is asbestos-linked MM that is etiologically linked to repeated asbestos exposure with a long latency period, although non-asbestos MM has also been reported.…
Read MoreMesothelioma Biomarkers: A Review Highlighting Contributions from the Early Detection Research Network
Cancer Epidemiology, Biomarkers, and Prevention 2020 July 22 [Link] Harvey I Pass, Marjan Alimi, Michele Carbone, Haining Yang, Chandra M Goparaju Abstract Background: Malignant Pleural Mesothelioma (MPM) is an asbestos related neoplasm which can only be treated successfully when correctly diagnosed and treated in early stages. The asbestos exposed population serves as a high risk…
Read MoreDelayed-Phase Enhancement for Evaluation of Malignant Pleural Mesothelioma on Computed Tomography: A Prospective Cohort Study
Clinical Lung Cancer 2020 June 14 [Link] Akash Patel, Leonid Roshkovan, Sally McNulty, Evan Alley, Drew A Torigian, Arun C Nachiappan, Maya Galperin-Aizenberg, Eduardo M Barbosa Jr, Joseph DiRienzi, Ian Berger, Urooj Khalid, Andrew R Haas, Sunil Singhal, E Paul Wileyto, Keith A Cengel, Sharyn I Katz Abstract Background: Radiologic assessment of malignant pleural mesothelioma…
Read MoreTesting for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology
Cancer Cytopathology 2020 July 17 [Link] Martin Chevrier, Sara E Monaco, Jacob A Jerome, Francoise Galateau-Salle, Andrew Churg, Sanja Dacic Abstract Background: A number of ancillary tests have been developed that aid in the diagnosis of mesothelioma in cytology specimens. The aim of this retrospective study was to determine whether testing for BAP1 and CDKN2A/p16…
Read MoreNucleolin and nucleophosmin expression patterns in pulmonary adenocarcinoma invading the pleura and in pleural malignant mesothelioma
Thoracic Cancer 2020 July 16 [Link] Marek Masiuk, Piotr Waloszczyk, Magdalena Lewandowska, Ewa Dobak, Elzbieta Urasinska Abstract Background: Visceral pleural invasion (VPI) in adenocarcinoma of the lung is considered a poor prognostic factor. The purpose of this study was to analyze nucleolin and nucleophosmin expression in pulmonary adenocarcinoma (PA) with VPI and in pleural malignant…
Read MoreVerification of a blood based targeted proteomics signature for malignant pleural mesothelioma
Cancer Epidemiol Biomarkers, July 30, 2020 (Epub ahead of print) [Link] Ferdinando Cerciello, et.al. Abstract Background: We have verified a mass spectrometry (MS) based targeted proteomics signature for the detection of malignant pleural mesothelioma (MPM) from the blood. Methods: A seven-peptide biomarker MPM signature by targeted proteomics in serum was identified in a previous independent…
Read MoreQuestioning the Prognostic Role of BAP-1 Immunohistochemistry in Malignant Pleural Mesothelioma: A Single Center Experience With Systematic Review and Meta-Analysis
Lung Cancer 2020 June 21 [Link] Luca Cantini, Federica Pecci, Alberto Murrone, Marco Tomasetti, Cecilia Copparoni, Ilaria Fiordoliva, Francesca Morgese, Silvia Rinaldi, Paola Mazzanti, Corrado Rubini, Alessia Cimadamore, Francesca Barbisan, Riccardo Giampieri, Marina Scarpelli, Lory Santarelli, Rossana Berardi Abstract Introduction: The prognostic role of BRCA1 associated protein-1 (BAP1) expression in malignant pleural mesothelioma (MPM) is…
Read MoreGenomic Profiling of Multiple Primary Cancers Including Synchronous Lung Adenocarcinoma and Bilateral Malignant Mesotheliomas: Identification of a Novel BAP1 Germline Variant
Pathology International 2020 June 24 [Link] Aya Shinozaki-Ushiku, Shinji Kohsaka, Hidenori Kage, Katsutoshi Oda, Kiyoshi Miyagawa, Jun Nakajima, Hiroyuki Aburatani, Hiroyuki Mano, Tetsuo Ushiku Abstract We report a case with a rare combination of synchronous lung adenocarcinoma and bilateral malignant pleural mesotheliomas in a 70-year-old male without asbestos exposure. He metachronously developed peritoneal malignant mesothelioma,…
Read More